BRAF Mutation Diversity and Impact on Clinical Outcomes in Non-Small Cell Lung Cancer

被引：0

作者：

Lu, K. ^{[1
]}

Shen, J. P. ^{[2
]}

Lopez-Diaz, F. J. ^{[3
]}

Leal, A. ^{[4
]}

Woodward, B. D. ^{[1
]}

Velcheti, V. ^{[4
]}

Riess, J. W. ^{[5
]}

Mansfield, A. S. ^{[6
]}

Salgia, R. ^{[7
]}

Husain, H. ^{[1
]}

机构：

[1] Univ Calif San Diego, La Jolla, CA USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] CEPIMP Genom, Cordoba, Argentina

[4] NYU Langone, New York, NY USA

[5] Univ Calif Davis, Sacramento, CA USA

[6] Mayo Clin, Rochester, MN USA

[7] City Hope Natl Med Ctr, Duarte, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

BRAF; NSCLC; Targeted Therapy;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.12C.01

引用

页码：S341 / S341

页数：1

共 50 条

[31] CLINICAL EXPERIENCE USE GEFITINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH A MUTATION EGFR [J].

Vozniy, Eduard ;

Popov, Anatoly ;

Galkin, Michail ;

Astrakhankina, Tamara .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) :S1214-S1214

[32] The Clinical Implication of Frameshift Indel Mutation Burden in Non-Small Cell Lung Cancer (NSCLC) [J].

Chae, Y. K. ;

Park, W. ;

Saravia, D. ;

Florou, V. ;

Chang, S. ;

Wang, S. ;

Cliec, L. ;

Rahbari, A. ;

Mohindra, N. ;

Villaflor, V. ;

Park, L. C. ;

Lopes, G. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :S423-S423

[33] Liquid Biopsy Mutation Profiling in Non-Small Cell Lung Cancer [J].

Gedvilaite, V. ;

Sestokaite, A. ;

Sabaliauskaite, R. ;

Jarmalaite, S. ;

Cicenas, S. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) :S256-S257

[34] Patterns of Osimertinib Dose-Reduction and Impact on Outcomes in EGFR-Mutation Positive Non-Small Cell Lung Cancer [J].

Ramagiri, L. ;

Farid, S. ;

Zhao, S. ;

Li, M. ;

To, B. ;

Amirmokhtari, N. ;

Wei, L. ;

Memmott, R. ;

Alahmadi, A. ;

He, K. ;

Kaufman, J. ;

Roof, L. ;

Shields, P. ;

Carbone, D. P. ;

Otterson, G. A. ;

Presley, C. J. ;

Owen, D. H. .

JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) :S620-S620

[35] Impact of biomarkers on non-small cell lung cancer treatment [J].

Luca Toschi ;

Federico Cappuzzo .

Targeted Oncology, 2010, 5 :5-17

[36] Impact of biomarkers on non-small cell lung cancer treatment [J].

Toschi, Luca ;

Cappuzzo, Federico .

TARGETED ONCOLOGY, 2010, 5 (01) :5-17

[37] Navigating the complexity of BRAF mutations in non-small cell lung cancer: current insights and future prospects [J].

Ibrahim, Sufyan ;

Shenoy, Smita ;

Kateel, Ramya ;

Hegde, Shreya ;

Parida, Amrita ;

Samantaray, Lipsita .

MULTIDISCIPLINARY RESPIRATORY MEDICINE, 2024, 19

[38] Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study [J].

Wang, Wenxian ;

Gu, Xiaodong ;

Si, Jinfei ;

Pu, Xingxiang ;

Wang, Liping ;

Chen, Huafei ;

Xu, Chunwei ;

Zhang, Xiaoyan ;

Yuan, Hongling ;

Lou, Guangyuan ;

Shao, Lan ;

Zhang, Gu ;

Song, Zhengbo .

GENES CHROMOSOMES & CANCER, 2022, 61 (09) :530-541

[39] The evolving treatment landscape for BRAF-mutated non-small cell lung cancer [J].

Dankner, Matthew ;

Maxwell, Jennifer ;

Rose, April A. N. .

TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (04) :930-935

[40] Outcomes of non-small cell lung cancer patients with non-V600E BRAF mutations: a series of case reports and literature review [J].

Lazar, Raluca ;

Fischbach, Cathie ;

Schott, Roland ;

Somme, Laura .

FRONTIERS IN ONCOLOGY, 2024, 14

← 1 2 3 4 5 →